Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

Association of tumor grade, enhancement on multiphasic CT and microvessel density in patients with clear cell renal cell carcinoma.

Coy H, Young JR, Pantuck AJ, Douek ML, Sisk A, Magyar C, Brown MS, Sayre J, Raman SS.

Abdom Radiol (NY). 2019 Oct 24. doi: 10.1007/s00261-019-02271-1. [Epub ahead of print]

PMID:
31650375
2.

The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.

Klatte T, Gallagher KM, Afferi L, Volpe A, Kroeger N, Ribback S, McNeill A, Riddick ACP, Armitage JN, 'Aho TF, Eisen T, Fife K, Bex A, Pantuck AJ, Stewart GD.

BMC Med. 2019 Oct 3;17(1):182. doi: 10.1186/s12916-019-1419-1.

3.

Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors.

Pooli A, Salmasi A, Johnson DC, Lenis AT, Faiena I, Lebacle C, Golla V, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2020 Jan;38(1):1.e17-1.e23. doi: 10.1016/j.urolonc.2019.08.016. Epub 2019 Sep 16.

PMID:
31537483
4.

Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients.

Heide J, Ribback S, Klatte T, Shariat S, Burchardt M, Dombrowski F, Belldegrun AS, Drakaki A, Pantuck AJ, Kroeger N.

World J Urol. 2019 Sep 13. doi: 10.1007/s00345-019-02930-4. [Epub ahead of print]

PMID:
31520111
5.

Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival.

Lenis AT, Burton CS, Golla V, Pooli A, Faiena I, Johnson DC, Salmasi A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2019 Sep;37(9):577.e9-577.e16. doi: 10.1016/j.urolonc.2019.03.009. Epub 2019 Mar 28.

PMID:
30930099
6.

Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.

Faiena I, Astrow SH, Elashoff DA, Jain R, Bot A, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A.

Cancer Immunol Immunother. 2019 May;68(5):743-751. doi: 10.1007/s00262-019-02316-w. Epub 2019 Feb 21.

PMID:
30790015
7.

Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?

Pooli A, Salmasi A, Faiena I, Lenis AT, Johnson DC, Lebacle C, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2019 Jan;37(1):63-70. doi: 10.1016/j.urolonc.2018.10.018. Epub 2018 Nov 13.

PMID:
30446452
8.

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A.

Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329.

9.

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha HS, Patel A, Lechuga M, Ravaud A.

Clin Cancer Res. 2019 Feb 15;25(4):1165-1173. doi: 10.1158/1078-0432.CCR-18-1724. Epub 2018 Nov 6.

10.

Association of the Gross Appearance of Intratumoral Vascularity at MDCT With the Carbonic Anhydrase IX Score in Clear Cell Renal Cell Carcinoma.

Young JR, Coy H, Kim HJ, Douek M, Sisk A, Pantuck AJ, Raman SS.

AJR Am J Roentgenol. 2018 Dec;211(6):1254-1258. doi: 10.2214/AJR.18.19725. Epub 2018 Oct 9.

PMID:
30300009
11.

Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines.

Upfill-Brown A, Lenis AT, Faiena I, Salmasi AH, Johnson DC, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

World J Urol. 2019 Jun;37(6):1157-1164. doi: 10.1007/s00345-018-2506-1. Epub 2018 Sep 28.

PMID:
30267197
12.

Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma.

Salmasi A, Faiena I, Lenis AT, Pooli A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Dec;36(12):527.e13-527.e19. doi: 10.1016/j.urolonc.2018.08.009. Epub 2018 Sep 15.

PMID:
30228094
14.

Clear cell renal cell carcinoma: identifying PTEN expression on multiphasic MDCT.

Young JR, Coy H, Kim HJ, Douek M, Sisk A, Pantuck AJ, Raman SS.

Abdom Radiol (NY). 2018 Dec;43(12):3410-3417. doi: 10.1007/s00261-018-1672-3.

PMID:
29946925
15.

Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A.

World J Urol. 2019 Jan;37(1):115-123. doi: 10.1007/s00345-018-2355-y. Epub 2018 Jun 1. Review.

PMID:
29858701
16.

Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.

Faiena I, Salmasi A, Mendhiratta N, Lenis AT, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

World J Urol. 2018 Nov;36(11):1825-1833. doi: 10.1007/s00345-018-2327-2. Epub 2018 May 11.

PMID:
29752514
17.

MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer.

Koutsioumpa M, Chen HW, O'Brien N, Koinis F, Mahurkar-Joshi S, Vorvis C, Soroosh A, Luo T, Issakhanian S, Pantuck AJ, Georgoulias V, Iliopoulos D, Slamon DJ, Drakaki A.

Mol Cancer Ther. 2018 Jul;17(7):1430-1440. doi: 10.1158/1535-7163.MCT-17-1049. Epub 2018 Apr 27.

18.

Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression.

Young JR, Coy H, Kim HJ, Douek M, Sisk A, Belldegrun A, Pantuck AJ, Raman SS.

Abdom Radiol (NY). 2018 Oct;43(10):2734-2742. doi: 10.1007/s00261-018-1546-8.

PMID:
29520426
19.

Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Faiena I, Salmasi A, Pantuck AJ, Drakaki A.

Eur Urol. 2018 Jun;73(6):981. doi: 10.1016/j.eururo.2018.01.023. Epub 2018 Feb 9. No abstract available.

PMID:
29433974
20.

Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy.

Salmasi A, Faiena I, Drakaki A, Pantuck AJ.

Eur Urol. 2018 Jul;74(1):119-121. doi: 10.1016/j.eururo.2018.01.036. Epub 2018 Feb 9. No abstract available.

PMID:
29433972
21.

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.

Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A.

Drug Des Devel Ther. 2018 Jan 23;12:209-215. doi: 10.2147/DDDT.S141491. eCollection 2018. Review.

22.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casey M, Laguerre B, Pandha HS, Pantuck AJ, Patel A, Lechuga MJ, Ravaud A.

Clin Cancer Res. 2018 Apr 1;24(7):1554-1561. doi: 10.1158/1078-0432.CCR-17-2822. Epub 2018 Jan 26.

23.

Trends in urinary diversion after radical cystectomy for urothelial carcinoma.

Bachour K, Faiena I, Salmasi A, Lenis AT, Johnson DC, Pooli A, Drakaki A, Pantuck AJ, Chamie K.

World J Urol. 2018 Mar;36(3):409-416. doi: 10.1007/s00345-017-2169-3. Epub 2018 Jan 3.

PMID:
29299664
24.

The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.

Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A.

Clin Genitourin Cancer. 2018 Apr;16(2):e269-e276. doi: 10.1016/j.clgc.2017.10.011. Epub 2017 Nov 3. Review.

PMID:
29199023
25.

Optimizing peptide epitope-based autoantibody detection in cancer patients.

Wang M, Lomeli SH, Franklin WA, Lee S, Pantuck AJ, Zeng G.

Am J Clin Exp Immunol. 2017 Nov 1;6(5):84-91. eCollection 2017.

26.

Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.

Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):78.e21-78.e28. doi: 10.1016/j.urolonc.2017.09.030. Epub 2017 Nov 8.

PMID:
29128421
27.

Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.

Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):79.e19-79.e26. doi: 10.1016/j.urolonc.2017.10.009. Epub 2017 Nov 2.

PMID:
29103965
28.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.

Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.

29.

Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.

Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, Pantuck AJ, Russo P, Cheng EH, Lee W, Tickoo SK, Ostrovnaya I, Creighton CJ, Papaemmanuil E, Seshan VE, Hakimi AA, Hsieh JJ.

JCI Insight. 2017 Jun 15;2(12). pii: 92688. doi: 10.1172/jci.insight.92688. eCollection 2017 Jun 15.

30.

Sarcomatoid Renal Cell Carcinoma and Collecting Duct Carcinoma: Discrimination From Common Renal Cell Carcinoma Subtypes and Benign RCC Mimics on Multiphasic MDCT.

Young JR, Young JA, Margolis DJA, Sauk S, Sayre J, Pantuck AJ, Raman SS.

Acad Radiol. 2017 Oct;24(10):1226-1232. doi: 10.1016/j.acra.2017.03.017. Epub 2017 May 18.

PMID:
28528853
31.

Clear Cell Renal Cell Carcinoma: Identifying the Loss of the Y Chromosome on Multiphasic MDCT.

Young JR, Coy H, Douek M, Lo P, Sayre J, Pantuck AJ, Raman SS.

AJR Am J Roentgenol. 2017 Aug;209(2):333-338. doi: 10.2214/AJR.16.17010. Epub 2017 May 15.

PMID:
28504543
32.

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.

Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N.

Urol Oncol. 2017 Feb;35(2):39.e1-39.e7. doi: 10.1016/j.urolonc.2016.09.006. Epub 2016 Oct 26.

PMID:
28341495
33.

Type 1 papillary renal cell carcinoma: differentiation from Type 2 papillary RCC on multiphasic MDCT.

Young JR, Coy H, Douek M, Lo P, Sayre J, Pantuck AJ, Raman SS.

Abdom Radiol (NY). 2017 Jul;42(7):1911-1918. doi: 10.1007/s00261-017-1091-x.

PMID:
28265706
34.

Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma.

Young JR, Coy H, Kim HJ, Douek M, Lo P, Pantuck AJ, Raman SS.

AJR Am J Roentgenol. 2017 Apr;208(4):812-819. doi: 10.2214/AJR.16.17152. Epub 2017 Jan 26.

PMID:
28125273
35.

Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility.

Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K.

Urol Oncol. 2017 May;35(5):272-278. doi: 10.1016/j.urolonc.2016.11.019. Epub 2017 Jan 3.

PMID:
28065395
36.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2016 Nov 15;4:81. eCollection 2016.

37.

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS.

JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419.

38.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators.

N Engl J Med. 2016 Dec 8;375(23):2246-2254. Epub 2016 Oct 9.

39.

Clear cell renal cell carcinoma: identifying the gain of chromosome 12 on multiphasic MDCT.

Young JR, Coy H, Douek M, Lo P, Sayre J, Pantuck AJ, Raman SS.

Abdom Radiol (NY). 2017 Jan;42(1):236-241. doi: 10.1007/s00261-016-0868-7.

PMID:
27519835
40.

Clear cell renal cell carcinoma: identifying the gain of chromosome 20 on multiphasic MDCT.

Young JR, Young JA, Margolis DJ, Sauk S, Pantuck AJ, Sayre J, Raman SS.

Abdom Radiol (NY). 2016 Nov;41(11):2175-2181.

PMID:
27315079
41.

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2170-5. doi: 10.1073/pnas.1525735113. Epub 2016 Feb 10.

42.

The Role of Adrenalectomy in Renal Cancer.

Weight CJ, Mulders PF, Pantuck AJ, Thompson RH.

Eur Urol Focus. 2016 Feb;1(3):251-257. doi: 10.1016/j.euf.2015.09.005. Epub 2015 Oct 3. Review.

PMID:
28723393
43.

A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.

Pantuck AJ, Pettaway CA, Dreicer R, Corman J, Katz A, Ho A, Aronson W, Clark W, Simmons G, Heber D.

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):242-8. doi: 10.1038/pcan.2015.32. Epub 2015 Jul 14.

PMID:
26169045
44.

Prognostication in localised renal cell carcinoma.

Kroeger N, Zimmermann U, Burchardt M, Pantuck AJ.

Lancet Oncol. 2015 Jun;16(6):603-4. doi: 10.1016/S1470-2045(15)70227-5. Epub 2015 May 12. No abstract available.

PMID:
25979596
45.

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.

Chamie K, Klöpfer P, Bevan P, Störkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ.

Urol Oncol. 2015 May;33(5):204.e25-33. doi: 10.1016/j.urolonc.2015.02.013. Epub 2015 Mar 29.

PMID:
25823535
46.

Pomegranate extract inhibits EMT in clear cell renal cell carcinoma in a NF-κB and JNK dependent manner.

An J, Guo Y, Wang T, Pantuck AJ, Rettig MB.

Asian J Urol. 2015 Jan;2(1):38-45. doi: 10.1016/j.ajur.2015.04.009. Epub 2015 Apr 16.

47.

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.

Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY.

Eur Urol. 2015 Sep;68(3):506-15. doi: 10.1016/j.eururo.2014.11.054. Epub 2014 Dec 15.

PMID:
25524810
48.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

49.

The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma.

Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, Shariat SF, Belldegrun AS, Klatte T.

Urol Oncol. 2015 Feb;33(2):68.e1-7. doi: 10.1016/j.urolonc.2014.08.005. Epub 2014 Sep 16.

PMID:
25240758
50.

Intermediate outcomes and predictors of efficacy in the radiofrequency ablation of 100 pathologically proven renal cell carcinomas.

McClure TD, Chow DS, Tan N, Sayre JA, Pantuck AJ, Raman SS.

J Vasc Interv Radiol. 2014 Nov;25(11):1682-8; quiz 1689. doi: 10.1016/j.jvir.2014.06.013. Epub 2014 Jul 28.

PMID:
25081202

Supplemental Content

Loading ...
Support Center